

## **Bio-Rad introduces Unity Next Peer QC**

written by CAP TODAY

October 14, 2022

Oct. 14, 2022—Bio-Rad Laboratories has launched Unity Next Peer QC, a quality control peer comparison software that provides instant access to peer reporting and comprehensive quality control data.



©2026 CAP TODAY, all rights reserved.

---

## **ZeptoMetrix releases flu, RSV, SARS-CoV-2 external run control**

written by CAP TODAY

October 14, 2022

Oct. 13, 2022—ZeptoMetrix has released its NATtrol external run control for flu A and B, RSV B, and SARS-CoV-2, for research use only.



©2026 CAP TODAY, all rights reserved.

---

## **mTuitive, Gestalt partner to enhance**

# [pathology reporting](#)

written by CAP TODAY  
October 14, 2022

Oct. 11, 2022—mTuitive and Gestalt Diagnostics announced a partnership to enhance reporting for pathology laboratories.



©2026 CAP TODAY, all rights reserved.

---

# [FDA clears NanoZoomer S360MD slide scanner system](#)

written by CAP TODAY  
October 14, 2022

Oct. 10, 2022—Hamamatsu Photonics announced that the FDA granted 510(k) clearance to market the NanoZoomer S360MD high-throughput, automated slide scanner system for primary diagnostic use.



©2026 CAP TODAY, all rights reserved.

---

# [Radox releases MRSA/MSSA PCR test on](#)

# Vivalytic system

written by CAP TODAY  
October 14, 2022

Oct. 7, 2022—Randox Laboratories has added its MRSA/SA test to the Vivalytic system.



©2026 CAP TODAY, all rights reserved.

---

# FDA clears Boston Cell Standards IHC controls for HER2, ER, PR

written by CAP TODAY  
October 14, 2022

Oct. 6, 2022—Boston Cell Standards today announced it received 510(k) clearance from the FDA for its IHControls breast cancer panel, positive controls to monitor the performance of the immunohistochemical staining process for HER2, ER, and PR IHC assays.



©2026 CAP TODAY, all rights reserved.

---

# Roche CDx approved to ID patients eligible for

## **Enhertu**

written by CAP TODAY  
October 14, 2022

Oct. 5, 2022—Roche announced that the FDA has approved the Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HER2-low metastatic breast cancer for whom Enhertu (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. Enhertu is a specifically engineered HER2-directed antibody drug conjugate developed and commercialized by AstraZeneca and Daiichi Sankyo.



©2026 CAP TODAY, all rights reserved.

---

## **NovoPath adds capabilities to NovoPath 360**

written by CAP TODAY  
October 14, 2022

Oct. 3, 2022—NovoPath today announced the release of enhanced integrated workflows to its software-as-a-service-based LIS platform, NovoPath 360.



©2026 CAP TODAY, all rights reserved.

---

## **Illumina unveils NovaSeq X series**

written by CAP TODAY  
October 14, 2022

Sept. 29, 2022—Illumina today announced the launch of the NovaSeq X series—NovaSeq X and NovaSeq X Plus—production-scale sequencers, which aim to enable faster, more powerful, and more sustainable sequencing.



©2026 CAP TODAY, all rights reserved.

---

## [Oncomine Dx Target test approved to ID patients for Retevmo](#)

written by CAP TODAY  
October 14, 2022

Sept. 28, 2022—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to aid in selecting patients with *RET*-fusion positive locally advanced or metastatic non-small cell lung cancer, *RET*-fusion positive advanced or metastatic thyroid cancer, and *RET*-mutation positive advanced or metastatic medullary thyroid cancer who may be eligible for treatment with Lilly’s Retevmo (selpercatinib).



©2026 CAP TODAY, all rights reserved.